Skip to Main Content
Try STAT+ TODAY
Trending:
Coronavirus
Pharmalot
First Opinion
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharmalot
STAT+

Just how many barriers do health insurers create to fair access to medicines?

  • Ed Silverman

By Ed Silverman Dec. 1, 2021

Reprints
red & yellow pill chart drug price controls
Adobe

Do large health insurers in the U.S. provide “fair access” to prescription medicines?

The answer to that question is nettlesome and elusive, at least according to a new analysis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed covers the pharmaceutical industry.

Tags

Create a display name to comment

This name will appear with your comment

Trending
HIPAA medical records abortion cases
HIPAA won’t protect you if prosecutors want your reproductive…
HIPAA won’t protect you if prosecutors want your reproductive health records
contraception abortion
Supreme Court decision suggests the legal right to contraception…
Supreme Court decision suggests the legal right to contraception is also under threat
Comparing the Pfizer and Moderna Covid vaccines for young…
Comparing the Pfizer and Moderna Covid vaccines for young children
Recommended
Dollars
‘A slippery slope’: Pfizer sells a contraceptive and donated…
‘A slippery slope’: Pfizer sells a contraceptive and donated to political groups that could come after…
Pharmalot Coming/Going STILL
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings
Pharmalittle: Senate Dems vet a tweaked version of drug-pricing…
Pharmalittle: Senate Dems vet a tweaked version of drug-pricing bill; biotechs double down on developing birth…

Recommended Stories

Dollars
Pharmalot

‘A slippery slope’: Pfizer sells a contraceptive and donated to political groups that could come after the company

By Ed Silverman

Pharmalot Coming/Going STILL
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Vascepa pill handout
Biotech

New analysis of Amarin’s Vascepa resurrects big questions about effectiveness

By Matthew Herper

JUUL display
Politics

What we know — and what we may never know — about why the FDA banned Juul

By Nicholas Florko

Descovy Truvada patient assistance program
Pharmalot

A ‘colossal financial fraud’: Gilead to get $33 million from a clinic for exploiting its HIV patient assistance program

By Ed Silverman